NewVac, LLC

NewVac LLC focuses on novel approaches to solid cancers therapy. To carry out its strategy NewVac has been developing a personalized therapeutic cancer vaccine, Oncophage, a new generation histone deacetylase inhibitor Quisinostat, low-molecular adjuvants and cancer diagnostic tools. Due to the importance of NewVac work in fighting cancer, the company was awarded grant for the drug development from Skolkovo Foundation.